sodium 1-(p-chlorobenzoyl)-2-methyl-5,6-methylenedioxy-3-indolylacetate | 37585-48-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: sodium 1-(p-chlorobenzoyl)-2-methyl-5,6-methylenedioxy-3-indolylacetate
• 英文别名: Sodium;2-[5-(4-chlorobenzoyl)-6-methyl-[1,3]dioxolo[4,5-f]indol-7-yl]acetate
• CAS: 37585-48-1
• 化学式: C₁₉H₁₃ClNO₅*Na
• 分子量: 393.759
• InChiKey: CSNQYVFCXMIKFT-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.68
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  80.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-Acyl-2-methyl-5,6-methylendioxy-3-indolylysaeure 在 sodium hydroxide 作用下， 以 水 、 丙酮 为溶剂， 生成 sodium 1-(p-chlorobenzoyl)-2-methyl-5,6-methylenedioxy-3-indolylacetate
  参考文献：
  名称：

  Novel N'-acylated phenyl-hydrazine and hydrozone derivatives

  摘要：

  新颖的吲哚乙酸衍生物具有出色的抗炎、退热和镇痛活性，其化学式如下：##SPC1## 其中X.sub.1和X.sub.2分别为氧和亚甲基中的一种；A为未取代的饱和碳链、未取代的不饱和碳链或取代的饱和或不饱和碳链，含有最多5个碳原子，取代基为卤素或苯基，碳链为直链或支链；m为0或1；n为1或2；R.sub.1和R.sub.2分别为氢或最多含有4个碳原子的烷基；R.sub.3为最多含有4个碳原子的烷基、未取代或较低烷基、较低烷氧基、较低烷硫基、硝基、氰基、亚甲二氧基、乙二氧基或卤素取代的芳基中的一种，烷基、烷氧基和烷硫基取代基含有最多4个碳原子，或未取代、卤素取代、烷基取代或苯基取代的苯环缩合、饱和或不饱和单环或多环脂环族，或被脂环族取代的烷基，或未取代、甲基取代、乙基取代或卤素取代的含氧、硫或氮原子的5-或6-成员杂环环族；R.sub.4为最多含有4个碳原子的烷基或氢，或M（其中M为阳离子）的一种。化学式（I）的吲哚乙酸通过将化合物与化合物反应制备而成：##SPC2## 其中X.sub.1、X.sub.2和n与上述定义相同，B为下列组成员之一：##EQU1## 和Z（其中Z为至少含有一个易于去除基团的氮保护体系），与化学式所代表的酸卤反应：R.sub.3--(A).sub.m--CO--hal（V）其中R.sub.3、A和m与上述定义相同，hal为卤素，得到化合物的N.sup.1-酰化产物：##SPC3## 其中X.sub.1、X.sub.2、R.sub.3、A、B、m和n与上述定义相同，然后将所得的N.sup.1-酰化产物（II）与下列化合物反应：##EQU2## 其中R.sub.1、R.sub.2和R.sub.4与上述定义相同。

  公开号：

  US03974145A1

文献信息

• US3974145A
  申请人：——

  公开号：US3974145A

  公开（公告）日：1976-08-10
• US4060550A
  申请人：——

  公开号：US4060550A

  公开（公告）日：1977-11-29
• Novel N'-acylated phenyl-hydrazine and hydrozone derivatives
  申请人：Sumitomo Chemical Company, Limited

  公开号：US03974145A1

  公开（公告）日：1976-08-10

  Novel indolylacetic acid derivatives, which have excellent anti-inflammatory, antipyretic and analgesic activities, represented by the formula, ##SPC1## Wherein X.sub.1 and X.sub.2 each is a member selected from the group consisting of oxygen and methylene; A is a member selected from the group consisting of unsubstituted saturated hydrocarbon chain having up to 5 carbon atoms, unsubstituted unsaturated hydrocarbon chain having up to 5 carbon atoms and substituted saturated or substituted ethylenically unsaturated hydrocarbon chain having up to 5 carbon atoms, in which the substituents are selected from the group consisting of halogen or phenyl, the hydrocarbon chain being straight or blanched one; m is 0 or 1; n is 1 or 2; R.sub.1 and R.sub.2 each is a member selected from the group consisting of hydrogen and alkyl having up to 4 carbon atoms; R.sub.3 is a member selected from the group consisting of alkyl having up to 4 carbon atoms, unsubstituted or a lower alkyl-, lower alkoxy-, lower alkylthio-, nitro-, cyano-, methylenedioxy-, ethylenedioxy- or halogen-substituted aryl, each of said alkyl, alkoxy and alkylthio substituents containing up to 4 carbon atoms, or unsubstituted, or halogen-, alkyl- or phenyl-substituted or benzene ring-condensed, saturated or unsaturated mono- or poly-aclicyclic group, or alkyl group substituted by said alicyclic group, or unsubstituted or methyl-, ethyl- or halogen-substituted 5- or 6-membered heterocyclic ring group containing oxygen, sulfur or nitrogen atom; R.sub.4 is a member selected from the group consisting of alkyl having up to 4 carbon atoms or hydrogen, or a group of M (wherein M is a cation). The indolylacetic acid of the formula (I) is prepared by reacting a compound of the formula, ##SPC2## Wherein X.sub.1, X.sub.2 and n are the same as defined above and B is a member selected from the group consisting of ##EQU1## and Z (wherein Z is a nitrogen protecting system comprising at least one readily removable group), with an acid halide represented by the formula, R.sub.3 --(A).sub.m --CO--hal (V) wherein R.sub.3, A and m are the same as defined above and hal is halogen, to obtain N.sup.1 -acylated compound of the formula, ##SPC3## Wherein X.sub.1, X.sub.2, R.sub.3, A, B, m and n are the same as defined above, then reacting the resultant N.sup.1 -acylated compound (II) with an aliphatic acid derivative represented by the formula, ##EQU2## wherein R.sub.1, R.sub.2 and R.sub.4 are the same as defined above.

  新颖的吲哚乙酸衍生物具有出色的抗炎、退热和镇痛活性，其化学式如下：##SPC1## 其中X.sub.1和X.sub.2分别为氧和亚甲基中的一种；A为未取代的饱和碳链、未取代的不饱和碳链或取代的饱和或不饱和碳链，含有最多5个碳原子，取代基为卤素或苯基，碳链为直链或支链；m为0或1；n为1或2；R.sub.1和R.sub.2分别为氢或最多含有4个碳原子的烷基；R.sub.3为最多含有4个碳原子的烷基、未取代或较低烷基、较低烷氧基、较低烷硫基、硝基、氰基、亚甲二氧基、乙二氧基或卤素取代的芳基中的一种，烷基、烷氧基和烷硫基取代基含有最多4个碳原子，或未取代、卤素取代、烷基取代或苯基取代的苯环缩合、饱和或不饱和单环或多环脂环族，或被脂环族取代的烷基，或未取代、甲基取代、乙基取代或卤素取代的含氧、硫或氮原子的5-或6-成员杂环环族；R.sub.4为最多含有4个碳原子的烷基或氢，或M（其中M为阳离子）的一种。化学式（I）的吲哚乙酸通过将化合物与化合物反应制备而成：##SPC2## 其中X.sub.1、X.sub.2和n与上述定义相同，B为下列组成员之一：##EQU1## 和Z（其中Z为至少含有一个易于去除基团的氮保护体系），与化学式所代表的酸卤反应：R.sub.3--(A).sub.m--CO--hal（V）其中R.sub.3、A和m与上述定义相同，hal为卤素，得到化合物的N.sup.1-酰化产物：##SPC3## 其中X.sub.1、X.sub.2、R.sub.3、A、B、m和n与上述定义相同，然后将所得的N.sup.1-酰化产物（II）与下列化合物反应：##EQU2## 其中R.sub.1、R.sub.2和R.sub.4与上述定义相同。